Patents by Inventor Duyan Nguyen

Duyan Nguyen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME
    Publication number: 20230143612
    Abstract: The present invention includes substituted 1,1?-biphenyl compounds, analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the invention can be used to treat, ameliorate, or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient. In another aspect, the compounds contemplated in the invention can be used to treat, ameliorate, and/or prevent cancer in a patient.
    Type: Application
    Filed: February 1, 2021
    Publication date: May 11, 2023
    Inventors: Vijay Ahuja, Yingzhi Bi, Andrew G. Cole, Bruce D. Dorsey, Yi Fan, Ramesh Kakarla, Sharon Marie Kirk, Duyan Nguyen, Seyma Ozturk, Jorge G. Quintero, Michael J. Sofia
  • Methods for preparing substituted pyridinone-containing tricyclic compounds
    Patent number: 11505551
    Abstract: The present disclosure relates to novel, scalable methods of making substituted tricyclic compounds that are useful to treat and/or prevent HBV and/or HBV-HDV infection and related conditions in a subject.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: November 22, 2022
    Assignee: Arbutus Biopharma Corporation
    Inventors: Shuai Chen, Bruce D. Dorsey, Dimitar B. Gotchev, Duyan Nguyen, Mahesh Kumar Pallerla, Ganapati Reddy Pamulapati
  • Substituted pyridinone-containing trycyclic compounds, and methods using same
    Patent number: 11013726
    Abstract: The present invention includes substituted pyridinone-containing tricyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection in a patient. In certain embodiments, the compounds and compositions of the invention inhibit and/or reduce HBsAg secretion.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: May 25, 2021
    Assignee: Arbutus Biopharma Corporation
    Inventors: Laurèn Danielle Bailey, Yingzhi Bi, Shuai Chen, Bruce D. Dorsey, Dimitar B. Gotchev, Richard James Holland, Ramesh Kakarla, Duyan Nguyen, Mark Christopher Wood
  • SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME
    Publication number: 20210052585
    Abstract: The present invention includes substituted 3,3?bis(phenoxymethyl)-1,1?-biphenyl compounds, analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.
    Type: Application
    Filed: March 29, 2019
    Publication date: February 25, 2021
    Inventors: Yingzhi Bi, Bruce D. Dorsey, Yi Fan, Christopher Brooks Moore, Duyan Nguyen
  • METHODS FOR PREPARING SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS
    Publication number: 20210032246
    Abstract: The present disclosure relates to novel, scalable methods of making substituted tricyclic compounds that are useful to treat and/or prevent HBV and/or HBV-HDV infection and related conditions in a subject.
    Type: Application
    Filed: April 11, 2019
    Publication date: February 4, 2021
    Inventors: Shuai Chen, Bruce D. Dorsey, Dimitar B. Gotchev, Duyan Nguyen, Mahesh Kumar Pallerla, Ganapati Reddy Pamulapati
  • Substituted pyridinone-containing trycyclic compounds, and methods using same
    Patent number: 10821103
    Abstract: The present invention includes substituted pyridinone-containing tricyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection in a patient. In certain embodiments, the compounds and compositions of the invention inhibit and/or reduce HBsAg secretion.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: November 3, 2020
    Assignee: Arbutus Biopharma Corporation
    Inventors: Laurèn Danielle Bailey, Yingzhi Bi, Shuai Chen, Bruce D. Dorsey, Dimitar B. Gotchev, Richard James Holland, Ramesh Kakarla, Duyan Nguyen, Mark Christopher Wood
  • SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME
    Publication number: 20200261432
    Abstract: The present invention includes substituted pyridinone-containing tricyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection in a patient. In certain embodiments, the compounds and compositions of the invention inhibit and/or reduce HBsAg secretion.
    Type: Application
    Filed: March 30, 2020
    Publication date: August 20, 2020
    Applicant: Arbutus Biopharma Corporation
    Inventors: Laurèn Danielle Bailey, Yingzhi Bi, Shuai Chen, Bruce D. Dorsey, Dimitar B. Gotchev, Richard James Holland, Ramesh Kakarla, Duyan Nguyen, Mark Christopher Wood
  • SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME
    Publication number: 20190314347
    Abstract: The present invention includes substituted pyridinone-containing tricyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection in a patient. In certain embodiments, the compounds and compositions of the invention inhibit and/or reduce HBsAg secretion.
    Type: Application
    Filed: November 3, 2017
    Publication date: October 17, 2019
    Inventors: Danielle Lauren BAILEY, Yingzhi BI, Shuai CHEN, Bruce D. DORSEY, Dimitar B. GOTCHEV, Richard James HOLLAND, Ramesh KAKARLA, Duyan NGUYEN, Mark Christopher WOOD
  • Urea inhibitors of MAP kinases
    Patent number: 7741479
    Abstract: The present invention is directed to a compound having the formula wherein R1, R2, G, and Q are defined herein. The compounds of the present invention are useful as inhibitors of protein kinases such as MAP kinases, in particular p38 kinases. The present invention is also directed to compositions comprising a compound according to the above formula. The compounds and compositions described herein are useful for treating and preventing an inflammatory condition or disease. The present invention is also directed to a method of treating or preventing a protein kinase-mediated condition.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: June 22, 2010
    Assignee: Locus Pharmaceuticals, Inc.
    Inventors: Enrique Luis Michelotti, Eric Bruce Springman, Duyan Nguyen, Rupa S. Shetty, Younghee Lee, Kristofer Kent Moffett, Jennifer Lee Ludington, Ted Tsutomis Fujimoto, Zenon D. Konteatis, Bin Liu, Frank Hollinger, Bruce D. Dorsey
  • UREA INHIBITORS OF MAP KINASES
    Publication number: 20100041642
    Abstract: Urea containing compounds that inhibit MAP kinases, pharmaceutical compositions including such compounds and methods for using these compounds to treat inflammatory diseases and cancer are described herein.
    Type: Application
    Filed: August 15, 2009
    Publication date: February 18, 2010
    Applicant: LOCUS PHARMACEUTICALS, INC.
    Inventors: Duyan NGUYEN, Martha KELLY, Kristofer MOFFETT, Enrique Luis MICHELOTTI, Bin Liu
  • Urea inhibitors of MAP kinases
    Publication number: 20060167247
    Abstract: The present invention is directed to a compound having the formula wherein R1, R2, G, and Q are defined herein. The compounds of the present invention are useful as inhibitors of protein kinases such as MAP kinases, in particular p38 kinases. The present invention is also directed to compositions comprising a compound according to the above formula. The compounds and compositions described herein are useful for treating and preventing an inflammatory condition or disease. The present invention is also directed to a method of treating or preventing a protein kinase-mediated condition.
    Type: Application
    Filed: December 7, 2005
    Publication date: July 27, 2006
    Inventors: Enrique Michelotti, Eric Springman, Duyan Nguyen, Rupa Shetty, Younghee Lee, Kristofer Moffett, Jennifer Ludington, Ted Fujimoto, Zenon Konteatis, Bin Liu, Frank Hollinger, Bruce Dorsey